252 related articles for article (PubMed ID: 32967858)
1. H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone.
Khazaei S; De Jay N; Deshmukh S; Hendrikse LD; Jawhar W; Chen CCL; Mikael LG; Faury D; Marchione DM; Lanoix J; Bonneil É; Ishii T; Jain SU; Rossokhata K; Sihota TS; Eveleigh R; Lisi V; Harutyunyan AS; Jung S; Karamchandani J; Dickson BC; Turcotte R; Wunder JS; Thibault P; Lewis PW; Garcia BA; Mack SC; Taylor MD; Garzia L; Kleinman CL; Jabado N
Cancer Discov; 2020 Dec; 10(12):1968-1987. PubMed ID: 32967858
[TBL] [Abstract][Full Text] [Related]
2. Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
Lutsik P; Baude A; Mancarella D; Öz S; Kühn A; Toth R; Hey J; Toprak UH; Lim J; Nguyen VH; Jiang C; Mayakonda A; Hartmann M; Rosemann F; Breuer K; Vonficht D; Grünschläger F; Lee S; Schuhmacher MK; Kusevic D; Jauch A; Weichenhan D; Zustin J; Schlesner M; Haas S; Park JH; Park YJ; Oppermann U; Jeltsch A; Haller F; Fellenberg J; Lindroth AM; Plass C
Nat Commun; 2020 Oct; 11(1):5414. PubMed ID: 33110075
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.
Yamamoto H; Iwasaki T; Yamada Y; Matsumoto Y; Otsuka H; Yoshimoto M; Kohashi K; Taguchi K; Yokoyama R; Nakashima Y; Oda Y
Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742
[TBL] [Abstract][Full Text] [Related]
4. Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells.
Fellenberg J; Sähr H; Mancarella D; Plass C; Lindroth AM; Westhauser F; Lehner B; Ewerbeck V
Cancer Lett; 2019 Apr; 448():61-69. PubMed ID: 30742944
[TBL] [Abstract][Full Text] [Related]
5. Significance of Histone H3.3 (G34W)-Mutant Protein in Pathological Diagnosis of Giant Cell Tumor of Bone.
Miskad UA; Syamsul F; Dahlan H; Sungowati NK; Achmad D; Johan MP
Asian Pac J Cancer Prev; 2023 May; 24(5):1737-1741. PubMed ID: 37247296
[TBL] [Abstract][Full Text] [Related]
6. Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.
Cottone L; Ligammari L; Lee HM; Knowles HJ; Henderson S; Bianco S; Davies C; Strauss S; Amary F; Leite AP; Tirabosco R; Haendler K; Schultze JL; Herrero J; O'Donnell P; Grigoriadis AE; Salomoni P; Flanagan AM
Cell Death Differ; 2022 Dec; 29(12):2459-2471. PubMed ID: 36138226
[TBL] [Abstract][Full Text] [Related]
7. The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing.
Lim J; Park JH; Baude A; Yoo Y; Lee YK; Schmidt CR; Park JB; Fellenberg J; Zustin J; Haller F; Krücken I; Kang HG; Park YJ; Plass C; Lindroth AM
Sci Rep; 2017 Oct; 7(1):13459. PubMed ID: 29044188
[TBL] [Abstract][Full Text] [Related]
8. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
[TBL] [Abstract][Full Text] [Related]
9. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone.
Amary F; Berisha F; Ye H; Gupta M; Gutteridge A; Baumhoer D; Gibbons R; Tirabosco R; O'Donnell P; Flanagan AM
Am J Surg Pathol; 2017 Aug; 41(8):1059-1068. PubMed ID: 28505000
[TBL] [Abstract][Full Text] [Related]
10. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Yamamoto H; Ishihara S; Toda Y; Oda Y
Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
[TBL] [Abstract][Full Text] [Related]
11. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
[TBL] [Abstract][Full Text] [Related]
12. Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone.
Yoshida KI; Nakano Y; Honda-Kitahara M; Wakai S; Motoi T; Ogura K; Sano N; Shibata T; Okuma T; Iwata S; Kawai A; Ichimura K; Yoshida A
Mod Pathol; 2019 Dec; 32(12):1751-1761. PubMed ID: 31285528
[TBL] [Abstract][Full Text] [Related]
13. [Expression of H3.3 G34W mutant-specific antibody in giant cell tumors of bone and its diagnostic value].
Wang X; Wu N; Zhang RS; Wei X; Ji RH; Ma HH; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):116-121. PubMed ID: 32074722
[No Abstract] [Full Text] [Related]
14. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
[TBL] [Abstract][Full Text] [Related]
15. Transcriptome and protein interaction profiling in cancer cells with mutations in histone H3.3.
Lim J; Park JH; Baude A; Fellenberg J; Zustin J; Haller F; Krücken I; Kang HG; Park YJ; Plass C; Lindroth AM
Sci Data; 2018 Dec; 5():180283. PubMed ID: 30532024
[TBL] [Abstract][Full Text] [Related]
16. Reliability and Role of Mutation-specific H3F3A (Histone 3-3) G34W Immunohistochemistry to Differentiate Giant Cell Tumor of Bone From its Clinicoradiologic and Histologic Mimics: An Institutional Study.
Pasricha S; Pruthi M; Jajodia A; Kumar A; Gupta G; Sharma A; Tiwari A; Rohela H; Durga G; Kamboj M; Koyyala VPB; Mehta A
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):36-41. PubMed ID: 34347625
[TBL] [Abstract][Full Text] [Related]
17. [Giant-cell tumor of bone in 2022].
Larousserie F; Audard V; Burns R; de Pinieux G
Ann Pathol; 2022 Apr; 42(3):214-226. PubMed ID: 35523609
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical Characterization of Giant Cell Tumor of Bone Treated With Denosumab: Support for Osteoblastic Differentiation.
Kerr DA; Brcic I; Diaz-Perez JA; Shih A; Wilky BA; Pretell-Mazzini J; Subhawong TK; Nielsen GP; Rosenberg AE
Am J Surg Pathol; 2021 Jan; 45(1):93-100. PubMed ID: 32773532
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
[TBL] [Abstract][Full Text] [Related]
20. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
Huang L; Xu J; Wood DJ; Zheng MH
Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
